Pregnancy is a precipitating factor for immune thrombotic thrombocytopenic purpura (iTTP). We compared the clinical course and outcomes of iTTP in women of reproductive age, between those with pregnancy- and non-pregnancy-related iTTP. A review of all reproductive-aged women diagnosed with iTTP during 2010–2019 in seven university hospitals in Israel. Of 42 cases of iTTP, 12 (28.6%) were pregnancy-related. At presentation, the laboratory profiles did not differ significantly between those with pregnancy- and non-pregnancy-related iTTP, including hemoglobin (median 8.4 vs 8.0 g/dL), platelet count (12.5 vs. 11.5 X 109/L); and levels of bilirubin (1.23 vs. 1.82 mg/dL), lactate dehydrogenase (1615 vs. 1701 U/L), creatinine (0.61 vs. 0.79 mg/dL) and anti-ADAMTS13 antibodies titer (75 vs. 82 U/mL). The proportions of women with renal, neurologic, or hepatic involvement were similar between the groups. Cardiac involvement was more common among those with pregnancy-related disease (25.0% vs. 3.3%, P = 0.06). The median number of courses of plasma-exchange therapy was 11 for both groups. All the women were treated with parenteral corticosteroids and the rate of adjunctive treatments did not differ between the groups (P = 0.30). Four women (one-third) with pregnancy-related disease had preeclampsia. Two women (16.7%) with pregnancy-related iTTP died during the acute episode (P = 0.07); no deaths were observed in the non-pregnancy-related group. Among reproductive-aged women with iTTP, most clinical and laboratory profiles were similar between those with pregnancy- and non-pregnancy-related disease. However, the higher rates of cardiac involvement and mortality among women with pregnancy-related iTTP highlight its challenging management.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Immune thrombotic thrombocytopenia purpura
Small for gestational age
Scully M, Thomas M, Underwood M et al (2014) Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 124:211–219
Tsai HM, Lian EC (1998) Antibodies to von Willebrand factorcleavingprotease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594
Furlan M, Robles R, Galbusera M et al (1998) Von willebrand factor-cleavingprotease in thrombotic thrombocytopenic purpura and thehemolytic-uremic syndrome. N Engl J Med 339(22):1578–1584
Vesely SK (2015) Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy. J Thromb Haemost 1:S216–S222
Ferrari B, Maino A, Lotta LA et al (2014) Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case-control study. Orphanet J Rare Dis 9:193
Moatti-Cohen M, Garrec C, Wolf M et al (2012) French reference center for thrombotic microangiopathies. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 119(24):5888–5897
von Auer C, von Krogh AS, Kremer Hovinga JA, Lämmle B (2015) Current insights into thrombotic microangiopathies: thrombotic thrombocytopenic purpura and pregnancy. Thromb Res 1:S30–S33
Sanchez-Luceros A, Farias CE, Amaral MM et al (2004) von Willebrand factor cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 92:1320–1326
Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98:2730–2735
Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, Canadian Apheresis Study Group (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325(6):393–397
Scully M, Hunt BJ, Benjamin S, British Committee for Standards in Haematology et al (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158:323–335
Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15(2):312–322
ACOG Practice Bulletin No. 202 (2019) Gestational hypertension and preeclampsia. Obstet Gynecol 133(1):e1–e25
Dollberg S, Haklai Z, Mimouni FB, Gorfein I, Gordon ES (2005) Birth weight standards in the live-born population in Israel. Isr Med Assoc J 7:311–314
Prevel R, Roubaud-Baudron C, Gourlain S et al (2019) Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival. Blood 134(24):2209–2217
Benhamou Y, Boelle PY, Baudin B et al (2015) Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 13(2):293–302
Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y (2007) The role of the immunesystem in preeclampsia. Mol Aspects Med 28(2):192–209
Sarno L, Stefanovic V, Maruotti GM, Zullo F, Martinelli P (2019) Thrombotic microangiopathies during pregnancy: the obstetrical and neonatal perspective. Eur J Obstet Gynecol Reprod Biol 237:7–12
Zheng L, Zhang D, Cao W, Song WC, Zheng XL (2019) Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood 134(13):1095–1105
Réti M, Farkas P, Csuka D et al (2012) Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 10(5):791–798
Teirilä L, Heikkinen-Eloranta J, Kotimaa J, Meri S, Lokki AI (2019) Regulation of the complement system and immunological tolerance in pregnancy. Semin Immunol 45:101337
Lisonkova S, Joseph KS (2013) Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 209:544.e1–544.e12
George JN, Nester CM, McIntosh JJ (2015) Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hematol Educ Program. 2015:644–648
Shira Dor’s participation in this study was performed in fulfillment of the research requirements toward the MD degree. We thank Ms. Cindy Cohen for her editorial assistance.
No external funding was used in this conduct of this study.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Human and animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the local institutional review board of each of the participating hospitals.
Institutional Review Board approval waiving informed consent was obtained for this retrospective study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Rottenstreich, A., Dor, S., Keren-Politansky, A. et al. Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age. J Thromb Thrombolysis 51, 187–193 (2021). https://doi.org/10.1007/s11239-020-02133-4
- Thrombotic thrombocytopenic purpura